UBS initiated coverage of Kaken Pharmaceutical (KKPCF) with a Neutral rating and 4,200 yen price target he firm says the company’s business stability is priced into the shares with limited catalysts ahead.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks